...
首页> 外文期刊>Seminars in Respiratory Infections >Utility of fibrinolytic agents for draining intrapleural infections.
【24h】

Utility of fibrinolytic agents for draining intrapleural infections.

机译:纤溶剂用于引流胸膜内感染的效用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Multiple studies have shown that the intrapleural instillation of fibrinolytic agents provides an effective and safe mode of treatment for complicated parapneumonic effusions and empyemas that decrease the need for surgical interventions. Although most investigators use streptokinase and urokinase, the technique of instillation is not standardized. The usual dose of streptokinase is 250,000 IU, but doses range from 50,000 to 220,000 IU for urokinase. Reported success rates range from 38% to 100%, but outcomes depend on the stage of progression of the parapneumonic effusion when fibrinolytics are employed. Fibrinolytics are more effective in complicated parapneumonic effusions than in established empyemas. Although complications of fibrinolytic therapy rarely occur, they result most often from allergic reactions to streptokinase. Urokinase is safer but more expensive. More randomized, comparative, controlled studies are needed to further define the most effective mode of fibrinolytic therapy for subgroups of patients with pleural infection.
机译:多项研究表明,胸膜内滴入纤溶剂可为复杂的肺炎旁积液和脓肿提供有效且安全的治疗方式,从而减少了手术干预。尽管大多数研究人员使用链激酶和尿激酶,但滴注技术尚未标准化。链激酶的常规剂量为250,000 IU,但尿激酶的剂量范围为50,000至220,000 IU。报告的成功率从38%到100%不等,但结局取决于使用纤溶剂时肺炎旁肺积液的进展阶段。与复杂的肺炎相比,纤维蛋白溶解剂在复杂的肺炎旁积液中更有效。尽管纤维蛋白溶解疗法的并发症很少发生,但最常见的是对链激酶的过敏反应。尿激酶更安全但更昂贵。需要更随机,比较,对照的研究来进一步确定针对胸膜感染患者亚组的纤溶治疗的最有效方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号